



Epidemiology of ESBL-Producing Enterobacteriaceae

Guest Editor:

Dr. Jiun-Ling Wang

National Cheng Kung University
Hospital, Tainan, Taiwan

Deadline for manuscript
submissions:

closed (28 February 2023)

Message from the Guest Editor

Dear Colleagues,

The emergence of ESBL (Extended spectrum beta-lactamase) -producing Enterobacteriaceae (or third generation cephalosporin resistant) lead to a challenge in the treatment of community-acquired and nosocomial infection. Higher percentage of ESBL-producing Enterobacteriaceae correlated with more treatment failure and more carbapenem use. There were some research gaps in the epidemiology, risk factors and transmission model of ESBL producing and MDR Enterobacteriaceae in different clinical settings. And more data in animal and environment distribution is necessary. We welcome the study about distribution and molecular characterization in antibiotic resistant genes in ESBL-producing Enterobacteriaceae. And antibiotic utilization patterns in patients with infection or decolonization strategies in asymptomatic carriers is also helpful to our readers.

Dr. Jiun-Ling Wang

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi